Trials / Conditions / Ocular Inflammation

Ocular Inflammation

25 registered clinical trials studyying Ocular Inflammation — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prosthese NCT05668455	Agnes	Phase 3
Unknown	Safety and Effectiveness of Drop-free Small Incision Cataract Surgery NCT05248139	Visualiza	N/A
Unknown	Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients Wi NCT05618730	Eximore Ltd.	Phase 1
Completed	Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery NCT04812951	Campus Bio-Medico University	EARLY_Phase 1
Completed	Biomarkers in Ocular Inflammation and Uveitis NCT04690829	National Eye Institute (NEI)	—
Recruiting	Dextenza in the Post-op Management of Vitreoretinal Surgeries NCT04371445	The Cleveland Clinic	Phase 4
Completed	Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 P NCT04374656	Johns Hopkins University	—
Completed	Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification NCT03580473	EMS	Phase 2
Completed	Corneal Epithelial Stem Cells and Dry Eye Disease NCT03302273	Sloan W. Rush, MD	N/A
Withdrawn	Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease NCT03408015	University of Alabama at Birmingham	Phase 4
Terminated	KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children NCT03596723	Kala Pharmaceuticals, Inc.	Phase 3
Completed	PGE2 Levels in Patient Treated With NSAIDs NCT03597867	University of Trieste	Phase 3
Completed	Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pteryg NCT03521791	Laboratorios Sophia S.A de C.V.	Phase 4
Completed	Closed Eye Neutrophils in Dry Eye Disease NCT03332342	University of Alabama at Birmingham	N/A
Completed	LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery NCT02786901	Bausch & Lomb Incorporated	Phase 3
Completed	RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - NCT02128113	Biogen	Phase 2
Completed	Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects NCT01808547	Sun Pharmaceutical Industries Limited	Phase 3
Withdrawn	Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Infla NCT01721694	Adapt Produtos Oftalmológicos Ltda.	Phase 3
Completed	Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects NCT01576952	Sun Pharmaceutical Industries Limited	Phase 3
Terminated	Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients NCT01214174	ICON Bioscience Inc	Phase 2
Completed	Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Ca NCT01190878	Sun Pharmaceutical Industries Limited	Phase 1 / Phase 2
Completed	Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Su NCT00699153	Bausch & Lomb Incorporated	Phase 3
Completed	Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surg NCT00645671	Bausch & Lomb Incorporated	Phase 3
Completed	Triamcinolone Versus Topical Treatment in Post Operative Phacoemulsification NCT00789971	Sligo General Hospital	N/A
Unknown	Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery NCT00353964	Evolutec Group	Phase 2